<DOC>
	<DOCNO>NCT00607607</DOCNO>
	<brief_summary>Patients treat MKC-1 , twice daily 14 consecutive day every four week ( cycle MKC-1 chemotherapy ) , disease progression unacceptable toxicity . Patients stratify Arm A ( ovarian cancer ) Arm B ( endometrial cancer ) , receive identical treatment regimen .</brief_summary>
	<brief_title>A Phase 2 Study Oral MKC-1 Patients With Ovarian Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>1 . Provide write informed consent ( HIPAA authorization release protect health information , applicable ) prior study related assessment . 2 . Histologically confirm epithelial ovarian cancer , primary peritoneal carcinomatosis , fallopian tube cancer , endometrial cancer . 3 . Age &gt; 18 year time consent . 4 . Arm A : Ovarian Cancer Patients : Must fail least one prior platinum base one taxane base chemotherapeutic regimen . [ Platinum failure define platinumrefractory ( progression receive platinumcontaining regimen ) platinumresistant ( disease progression within 6 month completion platinum contain regimen ) ] . Have measurable disease accord RECIST CA 125 criterion accord GCIG ( CA125 value &gt; 2 xULN ) . Have 3 prior regimen disease . Arm B : Endometrial Cancer Patients : Have 3 prior regimen disease Have measurable disease accord RECIST . 5 . ECOG performance status 0 , 1 , 2 . 6 . The following laboratory result , within 10 day MKC1 administration : Hemoglobin great equal 90 g/L ( 9 g/dL ) Absolute neutrophil count great equal 1.5 x 109/L Platelet count great equal 100 x 109/L Serum creatinine less equal 1.5 x ULN ( upper limit normal ) AST le equal 2.5 x ULN Serum Albumin great equal 30 g/L ( 3.0 g/dL ) Total bilirubin less equal ULN 1 . Administration cancer specific therapy within follow period prior study drug initiation : chemotherapy le 3 week prior ; hormonal therapy le one week prior ; radiation therapy le 2 week prior . 2 . Requirement paracentesis &gt; 2 liters/week . 3 . Pregnant breastfeed woman . Female patient must postmenopausal , surgically sterile , must agree use physical method contraception . Female patient childbearing potential must negative pregnancy test within 10 day first MKC1 administration . 4 . Known CNS metastases unless treat , clinically stable , require steroid . 5 . Clinical evidence significant bowel obstruction , active uncontrolled malabsorption syndrome , history total gastrectomy . 6 . Uncontrolled hypercalcemia ( serum calciumcorrected &gt; 3 mmol/L [ 12 mg/dL ] ) . 7 . Serious cardiac condition ( Class III/IV congestive heart failure accord New York Heart Association classification ) ; document acute myocardial infarction within previous 6 month . 8 . Any medical condition , investigator 's opinion , would impose excessive risk patient . These include : infection require parenteral oral antiinfective treatment , alter mental status , psychiatric condition would interfere understand informed consent . 9 . Patients previous malignancy unless free recurrence least 5 year except cure basal cell carcinoma skin carcinomainsitu uterine cervix . 10 . Treatment antiretroviral therapy metabolize CYP3A4 ( include indinavir , nelfinavir , ritonavir saquinavir ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>endometrial cancer</keyword>
</DOC>